Cat. No.: HY-P1515A

Copy Link Print Information

Angiotensin II (3-8), human TFA

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT₁ receptor.

For research use only. We do not sell to patients.

Purity: 99.14%
Formula: C₄₂H₅₅F₃N₈O₁₀
Molecular Weight:888.93

Storage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Angiotensin II (3-8), human TFA Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT₁ receptor.

IC₅₀ & Target

Angiotensin AT₁ receptor^[1].

All Angiotensin Receptor Isoforms :

In Vivo

Human Angiotensin II (3-8) causes endothelium-dependent renal cortical vasodilatation, in anaesthetized rats. At doses up to 125 pmol/kg, human Angiotensin II (3-8) is without any cardiovascular effects, but with doses of 1.25 and 12.5 nmol/kg there are dose-dependent increases in mean arterial blood pressure and reductions in renal and mesenteric flows and vascular conductances^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Appearance Solid
Molecular Weight 888.93
Formula C₄₂H₅₅F₃N₈O₁₀
Color White to off-white
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Theranostics

Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis. [Abstract]

2021 Jul 25;11(18):8624-8639. PMID: 34522203
Eur J Pharmacol

Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway. [Abstract]

2019 Jun 15:853:93-102. PMID: 30878387

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (56.25 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1249 mL

5.6247 mL

11.2495 mL

5 mM

0.2250 mL

1.1249 mL

2.2499 mL

10 mM

0.1125 mL

0.5625 mL

1.1249 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Protocol

Animal Administration^[1]

Rats^[1]
Male Long Evans rats (350-450 g) (n=7) are given increasing bolus doses of AII (1.25, 12.5 and 125 pmol/kg) or human Angiotensin II (3-8) (0.125, 1.25 and 12.5 nmol/kg) in random order, in the morning or afternoon of the same experimental day. Injections are separated by at least 20 min to allow variables to return to baseline^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	1.1249 mL	5.6247 mL	11.2495 mL	28.1237 mL
	5 mM	0.2250 mL	1.1249 mL	2.2499 mL	5.6247 mL
	10 mM	0.1125 mL	0.5625 mL	1.1249 mL	2.8124 mL
	15 mM	0.0750 mL	0.3750 mL	0.7500 mL	1.8749 mL
	20 mM	0.0562 mL	0.2812 mL	0.5625 mL	1.4062 mL
	25 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1249 mL
	30 mM	0.0375 mL	0.1875 mL	0.3750 mL	0.9375 mL
	40 mM	0.0281 mL	0.1406 mL	0.2812 mL	0.7031 mL
	50 mM	0.0225 mL	0.1125 mL	0.2250 mL	0.5625 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Angiotensin II (3-8), human TFA

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Angiotensin II (3-8), human TFA

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

FDA-Approved Drug Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Peptide Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Peptide Compound Library

High-Throughput Bioactive Compound Library

Neuropeptide Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Angiotensin II (3-8), human TFA

All Angiotensin Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Angiotensin II (3-8), human TFA

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

FDA-Approved Drug Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Peptide Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Peptide Compound Library

High-Throughput Bioactive Compound Library

Neuropeptide Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Angiotensin II (3-8), human TFA

All Angiotensin Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Angiotensin II (3-8), human TFA Related Classifications

HY-P1515A Related Classifications